Lower-cost insulin saves patients – and employers – money
Great news for diabetics! For the first time ever, our members have a lower-cost insulin option. We’re offering Humulin/Humalog insulin at a generic (Tier 1) copayment. And, we are moving Novolin/Novolog from a higher-cost Tier 2 or Tier 3 copayment. Here’s why we’re changing it:
-
To remove barriers to obtaining insulin. This supports our effort to promote the American Diabetes Association’s treatment guidelines.
-
To maintain quality. Humulin/Humalog is considered clinically equivalent and interchangeable with other brands of insulin. There are absolutely no quality concerns.
-
To reduce costs. Members commonly switch among the products, showing no true preference for one insulin over another.
-
It’s the right thing to do. Many members can’t afford their brand copayment, which often leads to decreased adherence (and thus higher long-term costs). By offering insulin as a generic, we can lower costs and improve the health of this high-risk population.
Now your employees are able to get – and take — their insulin at a lower cost. You’ll reap the benefits too since healthy employees are productive employees! Please contact your agent or account manager if you have questions about this new generic option.
Note: We’ve notified members affected by the insulin copayment changes and encouraged them to talk with their doctor about switching to a generic option.
Topics: Pharmacy
